Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.62 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.62 |
| ▸ | USP5 | P45974 | 7/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | VDR | P11473 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073487 | 1.00 | CSNK1D (0.62) | CSNK1DCSNK1G2USP5THRAVDR | |
| SCHEMBL14208796 | 0.92 | CSNK1D (0.55) | CSNK1DCSNK1G2USP5THRAVDR | |
| SCHEMBL4069592 | 0.78 | USP5 (0.54) | USP5THRAVDRCCR2OPRK1 | |
| SCHEMBL4882591 | 0.78 | USP5 (0.54) | USP5THRAVDRCCR2OPRK1 | |
| SCHEMBL4883051 | 0.76 | CSNK1D (1.00) | CSNK1DCSNK1G2CCR2LMNATP53 | |
| SCHEMBL4881149 | 0.76 | CSNK1D (0.55) | CSNK1DCSNK1G2OPRM1 | |
| SCHEMBL27764392 | 0.75 | CSNK1D (0.52) | CSNK1DCSNK1G2 | |
| SCHEMBL14112388 | 0.75 | USP5 (0.52) | USP5THRAVDRCCR2OPRK1 | |
| SCHEMBL14112389 | 0.75 | USP5 (0.52) | USP5THRAVDRCCR2OPRK1 | |
| SCHEMBL4076825 | 0.73 | USP5 (0.51) | USP5THRAVDRCCR2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | CSNK1D 1339/4885CSNK1G2 1657/4885USP5 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.